Of the 38 patients with KRAS information on both the CTCs and the tumor, one was KRAS wild-type in the primary tumor, and five patients had no detectable CTC, resulting in 32 tumor-CTC “pairs”: Six patients had no detected KRAS mutation in the CTCs (e.g. due to detection limitations), but in the primary tumor (18.7%). The gene discussed is KRAS; the disease is neoplasm.